{
  "source": "PA-Notification-Nubeqa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1291-6\nProgram Prior Authorization/Notification\nMedication Nubeqa® (darolutamide)\nP&T Approval Date 9/2019, 9/2020, 9/2021, 9/2022, 9/2023, 9/2024\nEffective Date 12/1/2024\n1. Background:\nNubeqa (darolutamide) is an androgen receptor inhibitor indicated for the treatment of patients\nwith non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-\nsensitive prostate cancer (mHSPC) in combination with docetaxel. Patients should also receive a\ngonadotropin-releasing hormone (GnRH) analog concurrently while taking Nubeqa or should have\nhad bilateral orchiectomy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age of\n19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Nubeqa will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Prostate Cancer\n1. Initial Authorization\na. Nubeqa will be approved based on all of the following criteria:\n(1) Diagnosis of prostate cancer\n-AND-\n(2) One of the following:\n(a) Both of the following:\n© 2024 UnitedHealthcare Services, Inc.\n1\ni. Disease is non-metastatic\n-AND-\nii. Disease is castration-resistant or recurrent\n-OR-\n(b) All of the following:\ni. Disease is metastatic\n-AND-\nii. Disease is hormone-sensitive\n-AND-\niii. Nubeqa will be used in combination with docetaxel\n-AND-\n(3) One of the following:\n(a) Used in combination with a gonadotropin-releasing hormone (GnRH)\nanalog [e.g., Lupron (leuprolide), Zoladex (goserelin), Tr",
    "ll be used in combination with docetaxel\n-AND-\n(3) One of the following:\n(a) Used in combination with a gonadotropin-releasing hormone (GnRH)\nanalog [e.g., Lupron (leuprolide), Zoladex (goserelin), Trelstar (triptorelin),\nVantas (histrelin), Firmagon (degarelix)]\n-OR-\n(b) Patient has had bilateral orchiectomy\nAuthorization will be issued for 12 months.\n2. Reauthorization Criteria\na. Nubeqa will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Nubeqa therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a\nCategory of Evidence and Consensus of 1, 2A, or 2B.\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Nubeqa [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; October\n2023.\n2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at\nhttps://www.nccn.org/professionals/drug_compendium/content/. Accessed July 26, 2024.\nProgram Prior Authorization/Notification – Nubeqa (darolutamide)\nChange Control\n9/2019 New program\n9/2020 Annual review with no changes to criteria. Updated references.\n9/2021 Annual review with no changes to coverage criteria. Updated\nformatting and references.\n9/2022 Annual ",
    "ol\n9/2019 New program\n9/2020 Annual review with no changes to criteria. Updated references.\n9/2021 Annual review with no changes to coverage criteria. Updated\nformatting and references.\n9/2022 Annual review. Added criteria for metastatic hormone-sensitive\nprostate cancer (mHSPC) and updated background. Added state\nmandate disclaimer and updated references.\n9/2023 Annual review with no changes to coverage criteria. Updated\nreferences.\n9/2024 Annual review with no changes. Updated references.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}